Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary modulation of intestinal integrity and functionality in weaned piglets using short-chain fructooligosaccharides, essential oils and sodium humate.

Frontiers in veterinary science·2026
Same author

Deoxynivalenol-induced apoptosis and IL-1β modulation by fosfomycin in porcine immune and human intestinal epithelial cells.

Veterinary research communications·2026
Same author

Practical oxygen therapy for newborn piglets.

New Zealand veterinary journal·2020
Same author

Fosfomycin residues in colostrum: Impact on morpho-physiology and microbiology of suckling piglets.

Journal of veterinary pharmacology and therapeutics·2018
Same author

Search for new physics in same-sign dilepton events in proton-proton collisions at [Formula: see text].

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the [Formula: see text] cross section in pp collisions at [Formula: see text] TeVand limits on anomalous gauge couplings.

The European physical journal. C, Particles and fields·2017

Related Experiment Video

Updated: Jun 10, 2026

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets
07:41

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets

Published on: September 13, 2022

Disodium-fosfomycin pharmacokinetics and bioavailability in post weaning piglets.

A L Soraci1, D S Perez, G Martinez

  • 1Área Toxicología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina. alejandro@vet.unicen.edu.ar

Research in Veterinary Science
|August 11, 2010
PubMed
Summary

This study investigated sodium fosfomycin pharmacokinetics in piglets, finding that a 15 mg/kg dose via intravenous or intramuscular injection achieves effective plasma concentrations for treating bacterial infections.

More Related Videos

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets
07:41

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets

Published on: September 13, 2022

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Area of Science:

  • Veterinary Pharmacology
  • Animal Health
  • Antimicrobial Pharmacokinetics

Background:

  • Fosfomycin is widely used in human medicine but lacks pharmacokinetic data in swine.
  • Weaning piglets are susceptible to infectious diseases, highlighting the need for effective treatments.
  • No prior studies document fosfomycin use or pharmacokinetics in piglets.

Purpose of the Study:

  • To determine the pharmacokinetics and bioavailability of sodium fosfomycin in post-weaning piglets.
  • To evaluate the efficacy of a 15 mg/kg dose administered intravenously (IV) and intramuscularly (IM).

Main Methods:

  • Sodium fosfomycin administered IV and IM at 15 mg/kg to piglets.
  • Plasma concentrations measured using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).
  • Key pharmacokinetic parameters calculated: AUC(0-12), Vd, CL, T(1/2), Cmax, Tmax, and bioavailability.

Main Results:

  • IV administration yielded AUC(0-12) of 120.00 ± 23.12 μg h/ml, Vd of 273.00 ± 40.70 ml/kg, CL of 131.50 ± 30.07 ml/kg/h, and T(1/2) of 1.54 ± 0.40 h.
  • IM administration resulted in Cmax of 43.00 ± 4.10 μg/ml, Tmax of 0.75 ± 0.00 h, AUC(0-12) of 99.00 ± 0.70 μg h/ml, and 85.5 ± 9.90% bioavailability.
  • Achieved concentrations exceed MIC90 values for Streptococcus sp. (0.25 μg/ml) and Escherichia coli (0.5 μg/ml).

Conclusions:

  • A 15 mg/kg dose of sodium fosfomycin provides effective plasma concentrations in piglets via both IV and IM routes.
  • These findings support the potential use of fosfomycin for treating bacterial infections in weaned piglets.
  • Further clinical studies are warranted to confirm efficacy in a field setting.